IP20-24: Blue Light Cystoscopy Enables Earlier CIS Recognition and Can Guide Risk-Appropriate Management of High-Risk Non–Muscle-Invasive Bladder Cancer: Real-World Outcomes from a U.S. Claims Cohort

IP20-24: Blue Light Cystoscopy Enables Earlier CIS Recognition and Can Guide Risk-Appropriate Management of High-Risk Non–Muscle-Invasive Bladder Cancer: Real-World Outcomes from a U.S. Claims Cohort

Friday, May 15, 2026 3:30 PM to 5:30 PM · 1 hr. 59 min. (America/New_York)
146A
Abstract

Log in

See all the content and easy-to-use features by logging in or registering!